TD-MF815010

Iv0165 is a rat IgG2a monoclonal antibody targeting CD8α. It is widely used to block CD8+ T cell activity in mice without depleting the cells in vivo. Functionally, Iv0165 can induce tolerance in xenograft transplantation models and reduce the incidence of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Structurally, Iv0165 binds CD8α at residues that overlap with the class I pMHC binding site, including Glu6, Arg8, and Glu27, forming hydrogen bonds with specific antibody residues (e.g., TyrL53, TyrH100, AsnL32). By occupying this epitope, Iv0165 likely interferes with CD8α interactions with class I MHC and TL molecules, blocking T cell co-receptor function.

Mouse

Neutralization

Rat

IgG2a, kappa

Iv0165

Monoclonal

T-cell surface glycoprotein CD8 alpha chain, T-cell surface glycoprotein Lyt-2, CD8a, Cd8a, Lyt-2, Lyt2

Please contact with the lab for this information.

>95% as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

P01731

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

SDS-PAGE for InVivoMAb Anti-Mouse CD8a/Lyt2 Antibody (Iv0165).

For research use only. Not suitable for clinical or therapeutic use.